Prodrugs Of Fumarates And Their Use In Treating Various Deseases

Patent No. EP2970101 (titled "Prodrugs Of Fumarates And Their Use In Treating Various Deseases") was filed by Alkermes Pharma Ireland on Mar 14, 2014. The application was issued on Sep 3, 2025.

Patent Summary

Novel prodrugs of monomethyl fumarate for treating neurological diseases, including multiple sclerosis, characterized by improved properties such as reduced gastrointestinal side effects, decreased food effect, and enhanced physical stability compared to dimethyl fumarate. The prodrugs are designed to provide sustained release of the active moiety, enabling once- or twice-daily dosing and improved patient compliance.

Patent Family

Patent Family

Patent Oppositions (4)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
GENERICS UKMar 6, 2019ELKINGTON AND FIFE
HEXALMar 6, 2019KRAUS & LEDERER
HEXALMar 6, 2019KRAUS & LEDERER PARTGMBB
TEVA PHARMACEUTICALSMar 5, 2019D YOUNG

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP2970101

ALKERMES PHARMA IRELAND
Application Number
EP14767892A
Filing Date
Mar 14, 2014
Status
Patent Maintained As Amended
Aug 1, 2025
Publication Date
Sep 3, 2025